MedTrace Logo

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

NCT05181839 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-09-04

No results posted yet for this study

Summary

An observational, prospective, mixed-methods study involving the integration of quantitative and qualitative data exploring the lived experience of burosumab-treated adolescents with XLH at the end of skeletal growth.

Conditions

  • X-Linked Hypophosphatemia

Interventions

DRUG

Burosumab

To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.

Sponsors & Collaborators

  • Kyowa Kirin Pharmaceutical Development Ltd

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-24
Primary Completion
2024-05-22
Completion
2024-05-22

Countries

  • France
  • Germany
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05181839 on ClinicalTrials.gov